DSE : IBP

Indo-Bangla Pharmaceuticals Limited

Pharmaceutical Preparations · Bangladesh

Last price 13.1 BDT (At close: Oct 29, 2026) · Market cap 1.52B

Latest research: Indo-Bangla Pharmaceuticals financial analysis: qualified FY2025 audit; FY2025 revenue 21.3% of FY2020 (Oct 2026) · Indo-Bangla Pharmaceuticals: revenue of BDT 184.2m in FY2025 against BDT 866.1m in FY2020, a qualified audit with a going-concern paragraph, and 9M FY2026 profit of BDT 2.8m

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Indo-Bangla Pharmaceuticals Limited engages in the manufacture and sale of various medicines, medical preparations drugs, and chemicals in Bangladesh and internationally. The company’s principal products include Omeprazole, Esomeprazole, Dexamethasone, Domperidone, Metronidazole, Montelukast, Paracetamol, Sildenafil Citrate, and several other formulations. It markets its products in various forms, such as tablets, capsules. Indo-Bangla Pharmaceuticals Limited was founded in 1954 and is based in Dhaka, Bangladesh.

Technical report: trend, RSI, support and resistance, charts

Reports